drugset / Trial / NCT06703177
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with advanced solid tumors.
Timeline
- Start
- 2025-02-18
- Primary completion
- 2026-01-01
- Completion
- 2027-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR-1826 | Unknown | — | — |
| Background | Adebrelimab | Monoclonal antibody | — | — |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Calcium folinate | Unknown | — | — |
| Background | Capecitabine | Small molecule | — | Oral |
| Background | SHR-4642 | Unknown | — | — |
| Background | SHR-8068 | Monoclonal antibody | — | — |
| Background | SHR-9839 | Unknown | — | — |
| Background | fluorouracil | Small molecule | — | — |